BioAge Labs (NASDAQ:BIOA) Stock Price Up 5.5% – Here’s What Happened

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price rose 5.5% on Friday . The company traded as high as $23.09 and last traded at $23.3710. 51,852 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 609,561 shares. The stock had previously closed at $22.16.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Needham & Company LLC assumed coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 target price on the stock. Roth Capital began coverage on BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target on the stock. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. BTIG Research initiated coverage on BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioAge Labs has an average rating of “Moderate Buy” and a consensus target price of $43.50.

BioAge Labs Price Performance

The company’s 50-day moving average is $19.78 and its 200-day moving average is $18.99. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -9.67 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. Sell-side analysts anticipate that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nano Cap New Millennium Growth Fund L P acquired a new position in BioAge Labs in the fourth quarter valued at $1,058,000. Y Intercept Hong Kong Ltd acquired a new stake in BioAge Labs during the first quarter worth about $3,521,000. Janus Henderson Group PLC raised its holdings in shares of BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the period. Bank of Nova Scotia purchased a new position in shares of BioAge Labs in the 1st quarter worth about $180,000. Finally, Stempoint Capital LP acquired a new position in shares of BioAge Labs in the 1st quarter valued at about $5,923,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.